Core Viewpoint - The global first dual receptor agonist for glucagon (GCG) and glucagon-like peptide-1 (GLP-1), Masitide Injection, developed by Innovent Biologics, has shown promising results in two Phase III clinical studies for type 2 diabetes patients in China, published in the prestigious journal Nature [1][2]. Group 1: Clinical Research Results - The DREAMS-1 and DREAMS-2 studies demonstrated that Masitide is superior to placebo and dulaglutide (1.5mg) in controlling blood sugar and weight loss, while also improving various cardiovascular, liver, and kidney-related indicators [2]. - The results of the weight loss Phase III study (GLORY-1) for Masitide were published in the New England Journal of Medicine (NEJM) in May [1]. Group 2: Future Developments - The DREAMS-3 trial, set to reach its primary endpoint in October 2025, will be the first global Phase III clinical trial comparing Masitide directly with semaglutide in diabetes treatment [2]. - Masitide has been approved in China for both diabetes and weight loss indications and has initiated seven Phase III studies covering diabetes, obesity, and related complications [3]. Group 3: Target Population - The ongoing Phase I clinical study for adolescent obesity has achieved its primary endpoint, indicating that Masitide can provide weight loss and multiple metabolic benefits for adolescents [3]. - A Phase III registration study for adolescent obesity will soon commence, marking the first such trial in China targeting weight loss in this demographic [3].
玛仕度肽两篇研究成果同期在《自然》发表